| Gliomas are the most common primary tumor in central nevous system (CNS), which malignant brain tumors affect the patients' life quality severely. There are about 40% patients with brain rumors diagnose gliomas. Despite advances in surgery treatment, radiotherapy and chemotherapy, the prognosis for patients with gliomas is poor. For an example, the current multimodality therapy for glioblastoma results in a median survival of less than 1 year. However, in the span of last tow decades, the understandings of the CNS immunology and glioma immunobiology have an exponential increase: The CNS has not been considered to be an immunologically "privileged" site. The role of microglia as ubiquitous professional antigen-presenting cells(APCs) within the CNS has been confirmed. The expression for MHC molecules of glioma has been detected in vitro and in vivo. These morden understandings promoted the development of new therapies to treat malignant brain tumor. Immunotherapy has been considered as a potential choice for patients with gliomas.The clinical immunotherapy protocols for patients with malignant glioma should be based upon demonstrated efficacy with animal experiments. An appropriate animal model is essential for reliability of experimental results. 9L/Fischer344, C6/Wistar or C6/SD rat glioma models have been currently employed for glioma therapy studies. Recently, some reports demonstrate that C6 cells expressing the haplotype RT1 gene in MHC is allogeneic to BDIX,BDX, SD and Wistar rat strains. Allogeneic C6/Wistar rat models present a lack of consistent tumor growth and even disappearance in the brain because of an anti-C6 immune graft rejection in vivo, that probably confounds interpreting the results of treatment. Limitations of the C6 rat glioma models implicate that they are inappropriate for glioma research, especially immunotherapy. Contrarily, the syngeneic 9L/Fischer344 model is currently available for studying immunotherapy protocols. Unfortunately, there are no 9L but almost C6 rat models been used in our country for glioma therapeutic studies, including immunotherapy and gene immunotherapy.hi this study, we take advantage of stereotactical technique to establish the 9L/Fischer344 rat intracerebral glioma model and observate the brain tumor biological characteristics. A comparative investigation between the 9L/Fischer344 and C6/Wistar rat intracerebral glioma models is done too. The results of these experiments demonstrate that the syngeneic 9L/Fischer344 rat glioma model is stable and repeatable, which is suit for glioma therapy study.Part one: The establishment of 9L/Fischer344 rat intracerebral gliomamodel. Objective:To establish the rat intracerebral glioma model of 9L/Fischer344. Method:1. Rat 9L gliosarcoma cell lines were propagated in Dulbecco's modified Eagle's medium, supplemented with 10% fetal calf serum, penicillin (l00U/ml), streptomycin (l00U/ml) and were incubated with 5% CO2 at 37 in a humidified chamber. The tumor cells were maintained hi continuous monolayer cell cultures in Corning tissue culture flasks. Confluent cells were collected, washed 3 tunes, resuspended in phosphate buffered saline (PBS), and counted in a hematocytometer to achieve a certain concentration.2. The 9L gliosarcoma cells were injected stereotactically into the rightcaudate nucleus of 35 syngeneic Fischer 344 rats. Rats were divided into 3 groups in random. Each rat received 5.0xl02, l.0xl05 and l.OxlO6 9L cells in a volume of 10-20, respectively.3. Implantation was followed by general observation. The survival time of each rat was recorded.4. MRI scanned on 10, 14 and 20 days after implantation for the rats which received l.OxlO5 9L cells.5. After the natural death, rat brains were sectioned and inspected. The tumor-containing samples were prepared by haematoxylin-eosin, immunohistochemiscal GFAP and S-100 protein stains. Tumor pathological characteristics were investigated with microscope.Result:1. All rats died within 50 days after injection of 9L cel...
|
PDF Full Text Request